International Journal of Hematology

, Volume 82, Issue 5, pp 417–421 | Cite as

Paroxysmal Nocturnal Hemoglobinuria

  • Mitsuhiro Omine
  • Taroh Kinoshita
  • Hideki Nakakuma
  • Jaroslaw P.Maciejewski
  • Charles J. Parker
  • Gérard Socié
Meeting Report

Key words

PNH PIG-A Clonal expansion Complement 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dacie JV, Lewis SM. Paroxysmal nocturnal hemoglobinuria: clinical manifestations, haematology, and nature of the disease. Ser Haematol. 1972;5:3–23.PubMedGoogle Scholar
  2. 2.
    Rosse WF. A short history of paroxysmal nocturnal hemoglobinuria: how we came to understand its natural history. In: Omine M, Kinoshita T, eds. Paroxysmal Nocturnal Hemoglobinuria and Related Disorders: Molecular Aspects of Pathogenesis. Tokyo: Springer; 2003:71–83.CrossRefGoogle Scholar
  3. 3.
    Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci USA. 1983;80:5066–5070.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Holguin MH, Fredrick LR, Bernshaw NJ, Wilcox LA, Parker CJ. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest. 1989;84:7–17.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Parker CJ. Historical aspects of paroxysmal nocturnal haemoglobinuria: ‘defining the disease’. Br J Haematol. 2002;117:3–22.CrossRefPubMedGoogle Scholar
  6. 6.
    Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73:703–711.CrossRefPubMedGoogle Scholar
  7. 7.
    Nagakura S, Ishihara S, Dunn DE, et al. Decreased susceptibility of leukemic cells with PIG-A mutation to natural killer cells in vitro. Blood. 2002;100:1031–1037.CrossRefPubMedGoogle Scholar
  8. 8.
    Murakami Y, Kosaka H, Maeda Y, et al. Inefficient response of T lymphocytes to glycosylphosphatidylinositol anchor-negative cells: implications for paroxysmal nocturnal hemoglobinuria. Blood. 2002;100:4116–4122.CrossRefPubMedGoogle Scholar
  9. 9.
    Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobin- uria-type cells in bone marrow failure syndrome. Blood. 2002;100:3897–3902.CrossRefPubMedGoogle Scholar
  10. 10.
    Inoue N, Murakami Y, Kinoshita T. Molecular genetics of paroxysmal nocturnal hemoglobinuria. Int J Hematol. 2003;77:107–112.CrossRefPubMedGoogle Scholar
  11. 11.
    Araten DJ, Nafa K, Pakdeesuwan K, Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci USA. 1999;96: 5209–5214.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Inoue N, Izui T, Kuwayama M, et al. A possible intrinsic mechanism for clonal expansion of PNH abnormal cells. In: Omine M, Kinoshita T, eds. Paroxysmal Nocturnal Hemoglobinuria and Related Disorders: Molecular Aspects of Pathogenesis. Tokyo: Springer; 2003:117–126.CrossRefGoogle Scholar
  13. 13.
    Lewis SM, Dacie JV. The aplastic anaemia-paroxysmal nocturnal haemoglobinuria syndrome. Br J Haematol. 1967;13:236–251.CrossRefPubMedGoogle Scholar
  14. 14.
    Tichelli A, Gratwohl A, Wursch A, Nissen C, Speck B. Late haematological complications in severe aplastic anaemia. Br J Haematol 1988;69:413–418.CrossRefPubMedGoogle Scholar
  15. 15.
    Nishimura J, Murakami Y, Kinoshita T. Paroxysmal nocturnal hemoglobinuria: an acquired genetic disease. Am J Hematol. 1999;62:175–182.CrossRefPubMedGoogle Scholar
  16. 16.
    Griscelli-Bennaceur A, Gluckman E, Scrobohaci ML, et al. Aplastic anemia and paroxysmal nocturnal hemoglobinuria: search for a pathogenetic link. Blood. 1995;85:1354–1363.PubMedGoogle Scholar
  17. 17.
    Schrezenmeier H, Hertenstein B, Wagner B, Raghavachar A, Heimpel H. A pathogenetic link between aplastic anemia and proxysmal nocturnal hemoglobinuria is suggested by a high frequency of aplastic anemia patients with a deficiency of phos- phatidylinositol glycan anchored proteins. Exp Hematol. 1995;23:81–87.PubMedGoogle Scholar
  18. 18.
    Azenishi Y, Ueda E, Machii T, et al. CD59-deficient blood cells and PIG-A gene abnormalities in Japanese patients with aplastic anaemia. Br J Haematol. 1999;104:523–529.CrossRefPubMedGoogle Scholar
  19. 19.
    Luzzatto L, Nafa K. Genetics of PNH. In: Young NS, Moss J, eds. Paroxysmal Nocturnal Hemoglobinuria and the Glycosylphos- phatidylinositol-Linked Proteins. New York, NY: Academic Press, 2000:21–47.Google Scholar
  20. 20.
    Parker CJ, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria: Recommendations of the International PNH Interest Group. Blood. In press.Google Scholar
  21. 21.
    Iwanaga M, Furukawa K, Amenomori T, et al. Paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes. Br J Haematol. 1998;102:465–474.CrossRefPubMedGoogle Scholar
  22. 22.
    Dunn DE, Tanawatthnacharoen P, Boccuni P, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Inter Med. 1999;132:401–408.CrossRefGoogle Scholar
  23. 23.
    Feng X, Chuhjo T, Sugimori C, et al. Diazepam-binding inhibitor- related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood. 2004;104:2425–2431.CrossRefPubMedGoogle Scholar
  24. 24.
    Bemba M, Guardiola P, Garderet L, et al. Bone marrow transplantation for paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1999;105:366–368.CrossRefPubMedGoogle Scholar
  25. 25.
    Raiola AM, Van Lint MT, Lamparelli T, et al. Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. Haematologica. 2000;85:59–62.PubMedGoogle Scholar
  26. 26.
    Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal haemoglobinuria. N Engl J Med. 1995;333:1253–1258.CrossRefPubMedGoogle Scholar
  27. 27.
    Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A. Late clonal diseases of treated aplastic anemia. Semin Hematol. 2000;37:91–101.CrossRefPubMedGoogle Scholar
  28. 28.
    Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003;101:1236–1242.CrossRefPubMedGoogle Scholar
  29. 29.
    Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood. 2002;100:3897–3902.CrossRefPubMedGoogle Scholar
  30. 30.
    Maciejewski JP, Follmann D, Nakamura R, et al. Incresased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood. 2001;98:3515–3519.CrossRefGoogle Scholar
  31. 31.
    Meyers G, Parker CJ. Management issues in paroxysmal nocturnal hemoglobinuria. Int J Hematol. 2003;77:125–132.CrossRefPubMedGoogle Scholar
  32. 32.
    Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2003;102:3587–3591.CrossRefPubMedGoogle Scholar
  33. 33.
    Nishimura JI, Kanakura Y, Ware RE, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004;83:193–207.CrossRefGoogle Scholar
  34. 34.
    Fujioka S, Asai T. Prognostic features of paroxysmal nocturnal hemoglobinuria in Japan. Nippon Ketsueki Gakkai Zasshi. 1989;52:1386–1394.PubMedGoogle Scholar
  35. 35.
    Socie G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet. 1996;348:573–577.CrossRefPubMedGoogle Scholar
  36. 36.
    Nishimura J, Phillips KL, Ware RE, et al. Efficient retrovirus-mediated PIG-A gene transfer and stable restoration of GPI-anchored protein expression in cells with the PNH phenotype. Blood. 2002;99:2748–2751.CrossRefGoogle Scholar
  37. 37.
    Parker CJ. An overview of the development of specific inhibitors of complement: opportunities for therapy of paroxysmal nocturnal hemoglobinuria. In Omine M, Kinoshita T, eds. Paroxysmal Nocturnal Hemoglobinuria and Related Disorders: Molecular Aspects of Pathogenesis. Tokyo: Springer; 2003:11–23.CrossRefGoogle Scholar
  38. 38.
    Hillmen PV, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350:552–559.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2005

Authors and Affiliations

  • Mitsuhiro Omine
    • 1
  • Taroh Kinoshita
    • 2
  • Hideki Nakakuma
    • 3
  • Jaroslaw P.Maciejewski
    • 4
  • Charles J. Parker
    • 5
  • Gérard Socié
    • 6
  1. 1.Division of HematologyInternal Medicine, Showa University Fujigaoka HospitalYokohama cityJapan
  2. 2.Department of Immunoregulation, Research Institute for Microbial DiseasesOsaka UniversityOsakaJapan
  3. 3.Department of Hematology/OncologyWakayama Medical UniversityWakayamaJapan
  4. 4.Experimental hematology and hematopoiesis sectionTaussig Cancer CenterClevelandUSA
  5. 5.Division of HematologyUniversity of Utah School of MedicineSalt Lake CityUSA
  6. 6.HématologieGreffe de moelle HôpitalSt Louis, ParisFrance

Personalised recommendations